Table 2.
Median concentrations of PGE2 in NAF and celecoxib in plasma in ng/ml based on celecoxib dose1
| Population: Dose | Before (N) | After (N) | After v. | P value | ||
| Treatment | Treatment | Before(N)2 | ΔPGE2 | Celecoxib Level & ΔPGE2 | ||
| 200 mg twice daily | ||||||
| Overall | PGE2 | 13.75(19) | 17.78(19) | 0.37(19) | 0.54 | 0.29 |
| Celecoxib | 223.7(19) | |||||
| Premenopausal | PGE2 | 13.75(5) | 21.85(5) | 5.50(5) | 0.63 | |
| Celecoxib | 117.6(5) | |||||
| Postmenopausal | PGE2 | 14.15(14) | 13.79(14) | -0.34(14) | 0.86 | |
| Celecoxib | 267.5(14) | |||||
| 400 mg twice daily | ||||||
| Overall | PGE2 | 13.80(22) | 13.22(22) | -1.72(22) | 0.83 | 0.006 |
| Celecoxib | 759.8(22) | |||||
| Premenopausal | PGE2 | 15.7(11) | 36.1(11) | 7.31(11) | 0.17 | |
| Celecoxib | 227.3(11) | |||||
| Postmenopausal | PGE2 | 8.33(11)3 | 6.81(11) | -4.95(11) | 0.03 | |
| Celecoxib | 860.6(11) | |||||
1: N: sample size; NAF: nipple aspirate fluid. P values assess ΔPGE2 (was the change from before to after treatment significant) and celecoxib level & ΔPGE2 (was the celecoxib level after treatment related to the change in PGE2)
2: Median change in PGE2 levels after treatment.
3: Only matched samples are included in this analysis, unlike the previous report which included PGE2 values for all subjects [16].